AzTrials
AzTrials

DementiaNCT06713070

Role of Gait Analysis in Different Type of Dementia

An observational study of Dementia and Gait Analysis, run by Assiut University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aim for the work is the studying of the existence and pattern of gait impairment in pre-dementia and dementia To examine the association between dual decline in gait and cognition Read more about this study

Who is it for?
Ages 30 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Dementia, Gait Analysis
How many people
102 participants
Where
1 siteEgypt
Study dates
12 Dec 2024to 10 Jan 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients aged 30 to 80 yrs old diagnosed with pre-dementia and/or dementia according to the Vascular Behavior and Cognitive Disorder (VASCOG) who are able to perform gait analysis tests

Who may be able to join

  • Patients aged 30-80 years. Patients with pre-dementia or dementia diagnosed according to VASCOG criteria. Ability to walk independently and perform gait assessment.

Who cannot join

  • History of clinically manifest cerebrovascular stroke. Definite lateralizing neurological signs. Severe cognitive impairment (MoCA score of 4). Spinal or orthopedic problems affecting gait. Long-term use or abuse of medications affecting cognition or balance. Clinical evidence of peripheral neuropathy.

Trial locations and contacts

1 site in 1 country.

Egypt1 site

  • Assiut University Hospitals

    Asyut, Assiut Governorate

Other trials in Egypt

About this study

Official title: Pattern of Gait Abnormality as a Predictor for Disease Progression in Dementia

Aim for the work is the studying of the existence and pattern of gait impairment in pre-dementia and dementia To examine the association between dual decline in gait and cognition

Read the detailed description

Dementia is a syndrome usually chronic,characterised by progressive global deterioration in intellect, including memory,learning,orientation,comprehension,judgment,gait, and balance

Gait and balance are the product of successful integration of various posture control mechanisms and locomotion.

There are two basic phases in the full cycle of the step Stance phase Swing phase Slow gait speeds are associated with both cognitive decline and greater risk of dementia So, our aim of this work is to study the existence and pattern of gait balance impairment in patients with different types of dementia and comparison with healthy elderly people.

Keywords
Dementia, Gait analysis, Prognosis
Medical subject headings
Dementia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06713070
Study groupRoleWhat they receive
Cohort 1 (Dementia)The group that will contain the diseased participants (Dementic patients able to walk and perform gait analysis)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gait Speed

    -Comparison of gait speed (m/s), measured using PODOSmart® instrumented insoles, between patients with dementia and healthy controls.

    Measured: Baseline assessment.

  2. Gait Symmetry

    Comparison of gait symmetry (%), measured using PODOSmart® instrumented insoles, between patients with dementia and healthy controls.

    Measured: Baseline assessment.

Secondary outcomes (7)

  1. Berg Balance Scale

    Comparison of Berg Balance Scale scores (0-56) between dementia patients and healthy controls.

    Measured: Baseline assessment

  2. Dynamic Gait Index

    Comparison of Dynamic Gait Index scores (0-24) between the two groups.

    Measured: Baseline assessment

  3. Timed Up and Go Test .

    Comparison of completion time (seconds) between the two groups.

    Measured: Baseline assessment

  4. Timed 25-Foot Walk Test

    Comparison of walking time (seconds) between the two groups.

    Measured: Baseline assessment

  5. Stride Length

    Comparison of stride length (cm), measured using PODOSmart®.

    Measured: Baseline assessment

  6. Cadence

    Comparison of cadence (steps/min), measured using PODOSmart®.

    Measured: Baseline assessment

  7. Stride Duration

    Comparison of stride duration (seconds), measured using PODOSmart®.

    Measured: Baseline assessment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Dec 2024
  2. Study start12 Dec 2024
  3. Primary completion15 Nov 2025
  4. Study completion10 Jan 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Other
Enrolment
102 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06713070
Sponsor's protocol ID
Gait analysis in dementia
Status last verified
Oct 2026
First submitted
2 Jun 2024
Last updated
4 Nov 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, Brayne C, Burns A, Cohen-Mansfield J, Cooper C, Costafreda SG, Dias A, Fox N, Gitlin LN, Howard R, Kales HC, Kivimaki M, Larson EB, Ogunniyi A, Orgeta V, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbaek G, Teri L, Mukadam N. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020 Aug 8;396(10248):413-446. doi: 10.1016/S0140-6736(20)30367-6. Epub 2020 Jul 30. No abstract available.

    PubMed 32738937

  • Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0.

    PubMed 23332364

  • Borson S, Raskind MA. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease. Neurology. 1997 May;48(5 Suppl 6):S17-24. doi: 10.1212/wnl.48.5_suppl_6.17s.

    PubMed 9153156

  • Rodriguez Garcia PL, Rodriguez Garcia D. Diagnosis of vascular cognitive impairment and its main categories. Neurologia. 2015 May;30(4):223-39. doi: 10.1016/j.nrl.2011.12.014. Epub 2012 Jun 26. English, Spanish.

    PubMed 22739039

  • Dicharry J. Kinematics and kinetics of gait: from lab to clinic. Clin Sports Med. 2010 Jul;29(3):347-64. doi: 10.1016/j.csm.2010.03.013.

    PubMed 20610026

  • Jayakody O, Breslin M, Srikanth VK, Callisaya ML. Gait Characteristics and Cognitive Decline: A Longitudinal Population-Based Study. J Alzheimers Dis. 2019;71(s1):S5-S14. doi: 10.3233/JAD-181157.

    PubMed 30958358

  • Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry. 2007 Sep;78(9):929-35. doi: 10.1136/jnnp.2006.106914. Epub 2007 Jan 19.

    PubMed 17237140

  • Moran C, Beare R, Phan TG, Bruce DG, Callisaya ML, Srikanth V; Alzheimer's Disease Neuroimaging Initiative (ADNI). Type 2 diabetes mellitus and biomarkers of neurodegeneration. Neurology. 2015 Sep 29;85(13):1123-30. doi: 10.1212/WNL.0000000000001982. Epub 2015 Sep 2.

    PubMed 26333802

  • Brach JS, Talkowski JB, Strotmeyer ES, Newman AB. Diabetes mellitus and gait dysfunction: possible explanatory factors. Phys Ther. 2008 Nov;88(11):1365-74. doi: 10.2522/ptj.20080016. Epub 2008 Sep 18.

    PubMed 18801861

  • Blumen HM, Brown LL, Habeck C, Allali G, Ayers E, Beauchet O, Callisaya M, Lipton RB, Mathuranath PS, Phan TG, Pradeep Kumar VG, Srikanth V, Verghese J. Gray matter volume covariance patterns associated with gait speed in older adults: a multi-cohort MRI study. Brain Imaging Behav. 2019 Apr;13(2):446-460. doi: 10.1007/s11682-018-9871-7.

    PubMed 29629501

  • Jayakody O, Breslin M, Beare R, Srikanth VK, Blumen HM, Callisaya ML. The Associations Between Grey Matter Volume Covariance Patterns and Gait Variability-The Tasmanian Study of Cognition and Gait. Brain Topogr. 2021 Jul;34(4):478-488. doi: 10.1007/s10548-021-00841-5. Epub 2021 Apr 29.

    PubMed 33914190

  • Rosano C, Studenski SA, Aizenstein HJ, Boudreau RM, Longstreth WT Jr, Newman AB. Slower gait, slower information processing and smaller prefrontal area in older adults. Age Ageing. 2012 Jan;41(1):58-64. doi: 10.1093/ageing/afr113. Epub 2011 Sep 28.

    PubMed 21965414

  • Srikanth V, Beare R, Blizzard L, Phan T, Stapleton J, Chen J, Callisaya M, Martin K, Reutens D. Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. Stroke. 2009 Jan;40(1):175-80. doi: 10.1161/STROKEAHA.108.524355. Epub 2008 Oct 16.

    PubMed 18927448

  • Del Campo N, Payoux P, Djilali A, Delrieu J, Hoogendijk EO, Rolland Y, Cesari M, Weiner MW, Andrieu S, Vellas B; MAPT/DSA Study Group. Relationship of regional brain beta-amyloid to gait speed. Neurology. 2016 Jan 5;86(1):36-43. doi: 10.1212/WNL.0000000000002235. Epub 2015 Dec 7.

    PubMed 26643548

  • Dias EN, da Silva JV, Pais-Ribeiro JL, Martins T. Validation of the advanced activities of daily living scale. Geriatr Nurs. 2019 Jan-Feb;40(1):7-12. doi: 10.1016/j.gerinurse.2018.05.008. Epub 2018 Jun 13.

    PubMed 29909023

Questions about this trial

What is this clinical trial studying?

An observational study of Dementia and Gait Analysis, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gait Speed (time frame: Baseline assessment.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06713070, which also lists 17 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in